PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific gene medicines, today announced that…
News + Press
PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific gene medicines, today announced that…
Download the poster here.
PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced…
PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for…
Philadelphia, PA – April 27, 2023 – Interius BioTherapeutics, a preclinical stage gene therapy company…
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
Company also celebrates “Deal of the Year” awarded by The Penn Center for Innovation PHILADELPHIA,…
Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.